From FDG and beyond: the evolving potential of nuclear medicine.
Artificial neural
Data analysis
Fibroblast activation protein inhibitor
Fluorodeoxyglucose
Positron emission tomography
Prostate-specific membrane antigen
Journal
Annals of nuclear medicine
ISSN: 1864-6433
Titre abrégé: Ann Nucl Med
Pays: Japan
ID NLM: 8913398
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
29
08
2023
accepted:
09
09
2023
pubmed:
26
9
2023
medline:
26
9
2023
entrez:
25
9
2023
Statut:
ppublish
Résumé
The radiopharmaceutical 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG) has been dominantly used in positron emission tomography (PET) scans for over 20 years, and due to its vast utility its applications have expanded and are continuing to expand into oncology, neurology, cardiology, and infectious/inflammatory diseases. More recently, the addition of artificial intelligence (AI) has enhanced nuclear medicine diagnosis and imaging with FDG-PET, and new radiopharmaceuticals such as prostate-specific membrane antigen (PSMA) and fibroblast activation protein inhibitor (FAPI) have emerged. Nuclear medicine therapy using agents such as [
Identifiants
pubmed: 37749301
doi: 10.1007/s12149-023-01865-6
pii: 10.1007/s12149-023-01865-6
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
583-595Informations de copyright
© 2023. The Author(s) under exclusive licence to The Japanese Society of Nuclear Medicine.
Références
Nutt R. The history of positron emission tomography. Mol Imaging Biol. 2002;4:11–26.
pubmed: 14538045
doi: 10.1016/S1095-0397(00)00051-0
Fukuda H, Matsuzawa T, Abe Y, Endo S, Yamada K, Kubota K, et al. Experimental study for cancer diagnosis with positron-labeled fluorinated glucose analogs: [
pubmed: 6981508
doi: 10.1007/BF00253423
Nishiyama Y, Kinuya S, Kato T, Kayano D, Sato S, Tashiro M, et al. Nuclear medicine practice in Japan: a report of the eighth nationwide survey in 2017. Ann Nucl Med. 2019;33:725–32.
pubmed: 31236776
doi: 10.1007/s12149-019-01382-5
Nensa F, Demircioglu A, Rischpler C. Artificial intelligence in nuclear medicine. J Nucl Med. 2019;60:29S-37S.
pubmed: 31481587
doi: 10.2967/jnumed.118.220590
Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, et al.
pubmed: 30954939
pmcid: 6581228
doi: 10.2967/jnumed.119.227967
Maurer T, Eiber M, Schwaiger M, Gschwend JE. Current use of PSMA–PET in prostate cancer management. Nat Rev Urol. 2016;13:226–35.
pubmed: 26902337
doi: 10.1038/nrurol.2016.26
Yan S, Zhang H, Wang J. Trends and hot topics in radiology, nuclear medicine and medical imaging from 2011–2021: a bibliometric analysis of highly cited papers. Jpn J Radiol. 2022;40:847–56.
pubmed: 35344133
pmcid: 8958482
doi: 10.1007/s11604-022-01268-z
Nakanishi K, Tanaka J, Nakaya Y, Maeda N, Sakamoto A, Nakayama A, et al. Whole-body MRI: detecting bone metastases from prostate cancer. Jpn J Radiol. 2022;40:229–44.
pubmed: 34693502
doi: 10.1007/s11604-021-01205-6
Wu Y, Feng T, Zhao Y, Xu T, Fu F, Huang Z, et al. Whole-body parametric imaging of
pubmed: 34385335
pmcid: 8973287
doi: 10.2967/jnumed.120.261651
Herrmann K, Kraus BJ, Hadaschik B, Kunikowska J, van Poppel H, N’Dow J, et al. Nuclear medicine theranostics comes of age. Lancet Oncol. 2021;22:1497–8.
pubmed: 34735807
doi: 10.1016/S1470-2045(21)00540-4
Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of
pubmed: 28076709
pmcid: 5895095
doi: 10.1056/NEJMoa1607427
Kostakoglu L, Agress H Jr, Goldsmith SJ. Clinical role of FDG PET in evaluation of cancer patients. Radiographics. 2003;23:315–40 (quiz 533).
pubmed: 12640150
doi: 10.1148/rg.232025705
DeBerardinis RJ, Chandel NS. We need to talk about the Warburg effect. Nat Metab. 2020;2:127–9.
pubmed: 32694689
doi: 10.1038/s42255-020-0172-2
Ide M, Suzuki Y. Is whole-body FDG-PET valuable for health screening? For. Eur J Nucl Med Mol Imaging. 2005;32:339–41.
pubmed: 15726352
doi: 10.1007/s00259-005-1774-3
Groheux D, Cochet A, Humbert O, Alberini J-L, Hindié E, Mankoff D.
pubmed: 26834096
doi: 10.2967/jnumed.115.157859
Kubicek GJ, Champ C, Fogh S, Wang F, Reddy E, Intenzo C, et al. FDG-PET staging and importance of lymph node SUV in head and neck cancer. Head Neck Oncol. 2010;2:19.
pubmed: 20637102
pmcid: 2915991
doi: 10.1186/1758-3284-2-19
Cerfolio RJ, Ojha B, Bryant AS, Bass CS, Bartalucci AA, Mountz JM. The role of FDG-PET scan in staging patients with nonsmall cell carcinoma. Ann Thorac Surg. 2003;76:861–6.
pubmed: 12963217
doi: 10.1016/S0003-4975(03)00888-9
Matsumoto Y. A pictorial essay on radiological changes after stereotactic body radiation therapy for lung tumors. Jpn J Radiol. 2022;40:647–63.
pubmed: 35184250
pmcid: 9252968
doi: 10.1007/s11604-022-01252-7
Hayashi K, Yamamoto N, Nakajima M, Nomoto A, Ishikawa H, Ogawa K, et al. Carbon-ion radiotherapy for octogenarians with locally advanced non-small-cell lung cancer. Jpn J Radiol. 2021;39:703–9.
pubmed: 33608792
pmcid: 8255258
doi: 10.1007/s11604-021-01101-z
Delbeke D, Rose DM, Chapman WC, Pinson CW, Wright JK, Beauchamp RD, et al. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. J Nucl Med. 1999;40:1784–91.
pubmed: 10565771
Inoue A, Ota S, Yamasaki M, Batsaikhan B, Furukawa A, Watanabe Y. Gastrointestinal stromal tumors: a comprehensive radiological review. Jpn J Radiol. 2022;40:1105–20.
pubmed: 35809209
pmcid: 9616766
doi: 10.1007/s11604-022-01305-x
Tanaka T, Kawashima A, Marukawa Y, Kitayama T, Masaoka Y, Kojima K, et al. Imaging evaluation of hereditary renal tumors: a pictorial review. Jpn J Radiol. 2021;39:619–32.
pubmed: 33759057
doi: 10.1007/s11604-021-01109-5
Kitao T, Shiga T, Hirata K, Sekizawa M, Takei T, Yamashiro K, et al. Volume-based parameters on FDG PET may predict the proliferative potential of soft-tissue sarcomas. Ann Nucl Med. 2019;33:22–31.
pubmed: 30196378
doi: 10.1007/s12149-018-1298-0
Nishimori M, Iwasa H, Nakaji K, Nitta N, Miyatake K, Yoshimatsu R, et al. Predicting the pathological invasiveness of early lung adenocarcinoma prior to surgery using Deauville criteria: reliability and validity. Jpn J Radiol. 2023;41:768–76.
pubmed: 36752955
pmcid: 10313578
doi: 10.1007/s11604-023-01397-z
Uchiyama Y, Hirata K, Watanabe S, Okamoto S, Shiga T, Okada K, et al. Development and validation of a prediction model based on the organ-based metabolic tumor volume on FDG-PET in patients with differentiated thyroid carcinoma. Ann Nucl Med. 2021;35:1223–31.
pubmed: 34379284
doi: 10.1007/s12149-021-01664-x
Takenaka J, Watanabe S, Abe T, Hirata K, Uchiyama Y, Kimura R, et al. Prognostic value of [
pubmed: 36301465
doi: 10.1007/s12149-022-01798-6
Bedmutha AS, Agrawal A, Rangarajan V, Goel M, Patkar S, Puranik AD, et al. Diagnostic performance of F-18 FDG PET/CT in recurrent adenocarcinoma gallbladder and its impact on post-recurrence survival. Jpn J Radiol. 2023;41:201–8.
pubmed: 36121626
doi: 10.1007/s11604-022-01340-8
Kitajima K, Watabe T, Nakajo M, Ishibashi M, Daisaki H, Soeda F, et al. Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using
pubmed: 34287739
doi: 10.1007/s11604-021-01174-w
Ben-Haim S, Ell P. 18F-FDG PET and PET/CT in the evaluation of cancer treatment response. J Nucl Med. 2009;50:88–99.
pubmed: 19139187
doi: 10.2967/jnumed.108.054205
Wong WL. PET-CT for staging and detection of recurrence of head and neck cancer. Semin Nucl Med. 2021;51:13–25.
pubmed: 33246535
doi: 10.1053/j.semnuclmed.2020.09.004
Suga K. F-18-FDG PET/CT findings of paraneoplastic dermatoses. Jpn J Radiol. 2022;40:863–75.
pubmed: 35713794
pmcid: 9441418
doi: 10.1007/s11604-022-01286-x
Ito H, Koyama T, Kanie Y, Morioka K, Nakaya M, Mitsumori A, et al. MRI, CT and FDG-PET/CT findings of Wolffian tumor: four-case series. Jpn J Radiol. 2021;39:1009–16.
pubmed: 34089476
pmcid: 8490215
doi: 10.1007/s11604-021-01145-1
Albano D, Bonacina M, Savelli G, Ferro P, Busnardo E, Gianolli L, et al. Clinical and prognostic
pubmed: 34272721
doi: 10.1007/s11604-021-01173-x
Simsek FS, Yuksel D, Yaylali O, Aslan HS, Kılıçarslan E, Bir F, et al. Can PET/CT be used more effectively in pleural effusion evaluation? Jpn J Radiol. 2021;39:1186–94.
pubmed: 34165683
doi: 10.1007/s11604-021-01155-z
Oki N, Ikebe Y, Koike H, Ideguchi R, Niino D, Uetani M. FDG-PET vs. chemical shift MR imaging in differentiating intertrabecular metastasis from hematopoietic bone marrow hyperplasia. Jpn J Radiol. 2021;39:1077–85.
pubmed: 34101119
pmcid: 8568862
doi: 10.1007/s11604-021-01149-x
Yoldaş B, Gürsoy S, Budak E, Gülmez B, Ceylan KC, Çırak AK, et al. FDG PET/CT signs of proven pulmonary hydatid cyst: is there any clue? Jpn J Radiol. 2022;40:1194–200.
pubmed: 35727457
doi: 10.1007/s11604-022-01296-9
He L, Chen Y, Tan X, Sun X, Zhang Q, Luo H, et al. 18F-FDG PET/CT and contrast-enhanced CT in the diagnosis of Castleman disease. Jpn J Radiol. 2023;41:98–107.
pubmed: 35895223
doi: 10.1007/s11604-022-01318-6
Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst. 2010;102:14–25.
pubmed: 20007921
pmcid: 2802286
doi: 10.1093/jnci/djp440
Minamimoto R. Series of myocardial FDG uptake requiring considerations of myocardial abnormalities in FDG-PET/CT. Jpn J Radiol. 2021;39:540–57.
pubmed: 33517516
pmcid: 8175248
doi: 10.1007/s11604-021-01097-6
Manabe O, Tamaki N. The future of cardiac disease assessment using
pubmed: 33893575
doi: 10.1007/s11604-021-01114-8
Vaidyanathan S, Patel CN, Scarsbrook AF, Chowdhury FU. FDG PET/CT in infection and inflammation—current and emerging clinical applications. Clin Radiol. 2015;70:787–800.
pubmed: 25917543
doi: 10.1016/j.crad.2015.03.010
Minamimoto R, Hotta M, Ishikane M, Inagaki T. FDG-PET/CT images of COVID-19: a comprehensive review. Glob Health Med. 2020;2:221–6.
pubmed: 33330811
pmcid: 7731428
doi: 10.35772/ghm.2020.01056
Minamimoto R. Optimal use of the FDG-PET/CT in the diagnostic process of fever of unknown origin (FUO): a comprehensive review. Jpn J Radiol. 2022;40:1121–37.
pubmed: 35781177
pmcid: 9616755
doi: 10.1007/s11604-022-01306-w
Wang S, Li B, Li P, Xie R, Wang Q, Shi H, et al. Feasibility of perfusion and early-uptake
pubmed: 34076855
doi: 10.1007/s11604-021-01140-6
Tamaki N, Hirata K, Kotani T, Nakai Y, Matsushima S, Yamada K. Four-dimensional quantitative analysis using FDG-PET in clinical oncology. Jpn J Radiol. 2023;41:831–42.
pubmed: 36947283
pmcid: 10366296
doi: 10.1007/s11604-023-01411-4
Xie Y, Teng Y, Jiang C, Ding C, Zhou Z. Prognostic value of
pubmed: 36752954
doi: 10.1007/s11604-023-01398-y
Ni M, Wang S, Liu X, Shi Q, Zhu X, Zhang Y, et al. Predictive value of intratumor metabolic and heterogeneity parameters on [
pubmed: 36219311
doi: 10.1007/s11604-022-01347-1
Iwasa H, Nagamachi S, Nakayama S, Yamamoto T, Yoshimitsu K. The reproducibility of MTV and TLG of soft tissue tumors calculated by FDG-PET: comparison between the lower limit by the fixed value SUV 2.5 and that value by 30% of SUVmax. Jpn J Radiol. 2023;41:531–40.
pubmed: 36637680
pmcid: 10147792
doi: 10.1007/s11604-022-01378-8
Mosleh-Shirazi MA, Nasiri-Feshani Z, Ghafarian P, Alavi M, Haddadi G, Ketabi A. Tumor volume-adapted SUVN as an alternative to SUVpeak for quantification of small lesions in PET/CT imaging: a proof-of-concept study. Jpn J Radiol. 2021;39:811–23.
pubmed: 33880686
doi: 10.1007/s11604-021-01112-w
Wei W, Jia G, Wu Z, Wang T, Wang H, Wei K, et al. A multidomain fusion model of radiomics and deep learning to discriminate between PDAC and AIP based on
pubmed: 36409398
doi: 10.1007/s11604-022-01363-1
Nakajo M, Jinguji M, Ito S, Tani A, Hirahara M, Yoshiura T. Clinical application of
doi: 10.1007/s11604-023-01476-1
pubmed: 37526865
Fang Y-HD, Lin C-Y, Shih M-J, Wang H-M, Ho T-Y, Liao C-T, et al. Development and evaluation of an open-source software package “CGITA” for quantifying tumor heterogeneity with molecular images. Biomed Res Int. 2014;2014: 248505.
pubmed: 24757667
pmcid: 3976812
doi: 10.1155/2014/248505
Nioche C, Orlhac F, Boughdad S, Reuzé S, Goya-Outi J, Robert C, et al. LIFEx: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity. Cancer Res. 2018;78:4786–9.
pubmed: 29959149
doi: 10.1158/0008-5472.CAN-18-0125
Hirata K, Kobayashi K, Wong K-P, Manabe O, Surmak A, Tamaki N, et al. A semi-automated technique determining the liver standardized uptake value reference for tumor delineation in FDG PET-CT. PLoS One. 2014;9: e105682.
pubmed: 25162396
pmcid: 4146536
doi: 10.1371/journal.pone.0105682
Larobina M, Megna R, Solla R. Comparison of three freeware software packages for
pubmed: 33595789
doi: 10.1007/s11604-021-01100-0
van Griethuysen JJM, Fedorov A, Parmar C, Hosny A, Aucoin N, Narayan V, et al. Computational radiomics system to decode the radiographic phenotype. Cancer Res. 2017;77:e104–7.
pubmed: 29092951
pmcid: 5672828
doi: 10.1158/0008-5472.CAN-17-0339
Hirata K, Sugimori H, Fujima N, Toyonaga T, Kudo K. Artificial intelligence for nuclear medicine in oncology. Ann Nucl Med. 2022;36:123–32.
pubmed: 35028877
doi: 10.1007/s12149-021-01693-6
Otaki Y, Miller RJH, Slomka PJ. The application of artificial intelligence in nuclear cardiology. Ann Nucl Med. 2022;36:111–22.
pubmed: 35029816
doi: 10.1007/s12149-021-01708-2
Matsubara K, Ibaraki M, Nemoto M, Watabe H, Kimura Y. A review on AI in PET imaging. Ann Nucl Med. 2022;36:133–43.
pubmed: 35029818
doi: 10.1007/s12149-021-01710-8
Nakao T, Hanaoka S, Nomura Y, Hayashi N, Abe O. Anomaly detection in chest 18F-FDG PET/CT by Bayesian deep learning. Jpn J Radiol. 2022;40:730–9.
pubmed: 35094221
pmcid: 9252947
doi: 10.1007/s11604-022-01249-2
Nai Y-H, Loi HY, O’Doherty S, Tan TH, Reilhac A. Comparison of the performances of machine learning and deep learning in improving the quality of low dose lung cancer PET images. Jpn J Radiol. 2022;40:1290–9.
pubmed: 35809210
doi: 10.1007/s11604-022-01311-z
Li Q, Li Y, Yuan H, Yang F, Huang Y, Song X, et al. PET morphology helps distinguish solitary and solid pulmonary tuberculosis from non-small cell lung cancer. Jpn J Radiol. 2023;41:312–21.
pubmed: 36227458
Okuyama C, Higashi T, Ishizu K, Saga T. FDG-PET findings associated with various medical procedures and treatments. Jpn J Radiol. 2023;41:459–76.
pubmed: 36575286
doi: 10.1007/s11604-022-01376-w
Morita Y, Nogami M, Sakaguchi K, Okada Y, Hirota Y, Sugawara K, et al. Enhanced release of glucose into the intraluminal space of the intestine associated with metformin treatment as revealed by [
pubmed: 32493754
doi: 10.2337/dc20-0093
Yamane T, Matsusaka Y, Fukushima K, Seto A, Matsunari I, Kuji I. Atlas of non-pathological solitary or asymmetrical skeletal muscle uptake in [
pubmed: 35344131
pmcid: 9345840
doi: 10.1007/s11604-022-01264-3
Yuan H, Tan X, Sun X, He L, Li D, Jiang L. Role of
pubmed: 36480105
doi: 10.1007/s11604-022-01369-9
Pijl JP, Nienhuis PH, Kwee TC, Glaudemans AWJM, Slart RHJA, Gormsen LC. Limitations and Pitfalls of FDG-PET/CT in Infection and Inflammation. Semin Nucl Med. 2021;51:633–45.
pubmed: 34246448
doi: 10.1053/j.semnuclmed.2021.06.008
Surasi DS, Bhambhvani P, Baldwin JA, Almodovar SE, O’Malley JP.
pubmed: 24503347
doi: 10.2967/jnmt.113.132621
Krarup MMK, Fischer BM, Christensen TN. New PET tracers: current knowledge and perspectives in lung cancer. Semin Nucl Med. 2022;52:781–96.
pubmed: 35752465
doi: 10.1053/j.semnuclmed.2022.05.002
Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene. 2008;27:5904–12.
pubmed: 18836471
pmcid: 3689267
doi: 10.1038/onc.2008.271
de Visser KE, Joyce JA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41:374–403.
pubmed: 36917948
doi: 10.1016/j.ccell.2023.02.016
Loktev A, Lindner T, Mier W, Debus J, Altmann A, Jäger D, et al. A tumor-imaging method targeting cancer-associated fibroblasts. J Nucl Med. 2018;59:1423–9.
pubmed: 29626120
pmcid: 6126438
doi: 10.2967/jnumed.118.210435
Mori Y, Dendl K, Cardinale J, Kratochwil C, Giesel FL, Haberkorn U. FAPI PET: fibroblast activation protein inhibitor use in oncologic and nononcologic disease. Radiology. 2023;306: e220749.
pubmed: 36594838
doi: 10.1148/radiol.220749
Zhang Z, Jia G, Pan G, Cao K, Yang Q, Meng H, et al. Comparison of the diagnostic efficacy of
pubmed: 35243518
doi: 10.1007/s00259-022-05729-5
Lang M, Spektor A-M, Hielscher T, Hoppner J, Glatting FM, Bicu F, et al. Static and dynamic
pubmed: 35906094
pmcid: 9902850
doi: 10.2967/jnumed.122.264361
Zhang J, He Q, Jiang S, Li M, Xue H, Zhang D, et al. [
pubmed: 36346437
doi: 10.1007/s00259-022-06022-1
Wei Y, Ma L, Li P, Lu J, Ren J, Yan S, et al. FAPI compared with FDG PET/CT for diagnosis of primary and metastatic lung cancer. Radiology. 2023;308: e222785.
pubmed: 37552075
doi: 10.1148/radiol.222785
Demmert TT, Maric I, Pomykala KL, Lueckerath K, Siveke J, Schaarschmidt BM, et al. Novel
pubmed: 36396454
pmcid: 10071804
doi: 10.2967/jnumed.122.264872
Wass G, Clifford K, Subramaniam RM. Evaluation of the diagnostic accuracy of FAPI PET/CT in oncologic studies: systematic review and metaanalysis. J Nucl Med. 2023;64:1218–24.
pubmed: 37290798
doi: 10.2967/jnumed.123.265471
Hotta M, Rieger AC, Jafarvand MG, Menon N, Farolfi A, Benz MR, et al. Non-oncologic incidental uptake on FAPI PET/CT imaging. Br J Radiol. 2023;96:20220463.
pubmed: 35776566
doi: 10.1259/bjr.20220463
Bentestuen M, Al-Obaydi N, Zacho HD. FAPI-avid nonmalignant PET/CT findings: an expedited systematic review. Semin Nucl Med. 2023;53:694–705.
pubmed: 36813670
doi: 10.1053/j.semnuclmed.2023.02.001
Luo Y, Pan Q, Zhou Z, Li M, Wei Y, Jiang X, et al.
pubmed: 36853178
doi: 10.1148/radiol.222052
Scharitzer M, Macher-Beer A, Mang T, Unger LW, Haug A, Reinisch W, et al. Evaluation of intestinal fibrosis with
pubmed: 36853176
doi: 10.1148/radiol.222389
Song W, Zhang X, He S, Gai Y, Qin C, Hu F, et al.
pubmed: 36269382
doi: 10.1007/s00259-022-05994-4
Gu Y, Han K, Zhang Z, Zhao Z, Yan C, Wang L, et al.
pubmed: 35322381
doi: 10.1007/s12350-022-02952-3
Song L, Zan C, Liang Z, Chen X, Li J, Ren N, et al. Potential value of FAPI PET/CT in the detection and treatment of fibrosing mediastinitis: preclinical and pilot clinical investigation. Mol Pharm. 2023;20:4307–18.
pubmed: 37486106
doi: 10.1021/acs.molpharmaceut.3c00452
Liu Y, Watabe T, Kaneda-Nakashima K, Shirakami Y, Naka S, Ooe K, et al. Fibroblast activation protein targeted therapy using [
pubmed: 34537893
doi: 10.1007/s00259-021-05554-2
Farolfi A, Calderoni L, Mattana F, Mei R, Telo S, Fanti S, et al. Current and emerging clinical applications of PSMA PET diagnostic imaging for prostate cancer. J Nucl Med. 2021;62:596–604.
pubmed: 33712536
doi: 10.2967/jnumed.120.257238
Swiha M, Ayati N, Oprea-Lager DE, Ceci F, Emmett L. How to report PSMA PET. Semin Nucl Med [Internet]. 2023. https://doi.org/10.1053/j.semnuclmed.2023.07.007 .
doi: 10.1053/j.semnuclmed.2023.07.007
pubmed: 37558507
Duan H, Iagaru A. PSMA PET for detection of recurrence. Semin Nucl Med [Internet]. 2023. https://doi.org/10.1053/j.semnuclmed.2023.07.002 .
doi: 10.1053/j.semnuclmed.2023.07.002
pubmed: 37567795
Lawal IO, Ndlovu H, Kgatle M, Mokoala KMG, Sathekge MM. Prognostic value of PSMA PET/CT in prostate cancer. Semin Nucl Med [Internet]. 2023. https://doi.org/10.1053/j.semnuclmed.2023.07.003 .
doi: 10.1053/j.semnuclmed.2023.07.003
pubmed: 37482489
Kind F, Eder A-C, Jilg CA, Hartrampf PE, Meyer PT, Ruf J, et al. Prognostic value of tumor volume assessment on PSMA PET after
pubmed: 36302658
doi: 10.2967/jnumed.122.264489
Seifert R, Rasul S, Seitzer K, Eveslage M, Rahbar Nikoukar L, Kessel K, et al. A Prognostic risk score for prostate cancer based on PSMA PET-derived organ-specific tumor volumes. Radiology. 2023;307: e222010.
pubmed: 37070991
doi: 10.1148/radiol.222010
Gafita A, Djaileb L, Rauscher I, Fendler WP, Hadaschik B, Rowe SP, et al. Response evaluation criteria in PSMA PET/CT (RECIP 1.0) in metastatic castration-resistant prostate cancer. Radiology. 2023;308: e222148.
pubmed: 37432081
doi: 10.1148/radiol.222148
Holzgreve A, Unterrainer M, Calais J, Adams T, Oprea-Lager DE, Goffin K, et al. Is PSMA PET/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial. Eur J Nucl Med Mol Imaging [Internet]. 2023. https://doi.org/10.1007/s00259-023-06332-y .
doi: 10.1007/s00259-023-06332-y
pubmed: 37642707
Vetrone L, Fortunati E, Castellucci P, Fanti S. Future imaging of prostate cancer: do we need more than PSMA PET/CT? Semin Nucl Med [Internet]. 2023. https://doi.org/10.1053/j.semnuclmed.2023.06.004 .
doi: 10.1053/j.semnuclmed.2023.06.004
pubmed: 37394289
Hirata K, Yamaguchi S, Shiga T, Kuge Y, Tamaki N. The roles of hypoxia imaging using
Hirata K, Terasaka S, Shiga T, Hattori N, Magota K, Kobayashi H, et al.
pubmed: 22307533
doi: 10.1007/s00259-011-2037-0
Watanabe S, Takayanagi A, Hirata K, Inoue T, Okamoto S, Toyonaga T, et al. Combination of FDG and FMISO may predict accurate PFS in patients with early-stage NSCLC after stereotactic radiotherapy. J Nucl Med. 2019;60:150–150.
Nakajima K, Homma M, Suzuki M, Yokouchi Y, Matsuda T, Takakura H, et al. Reduction of tumor hypoxia by anti-PD-1 therapy assessed using pimonidazole and [
pubmed: 35367730
doi: 10.1016/j.nucmedbio.2022.03.005
Furuya S, Naya M, Manabe O, Hirata K, Ohira H, Aikawa T, et al.
pubmed: 31820409
doi: 10.1007/s12350-019-01976-6
Kroenke M, Hirata K, Gafita A, Watanabe S, Okamoto S, Magota K, et al. Voxel based comparison and texture analysis of
pubmed: 30818360
pmcid: 6394953
doi: 10.1371/journal.pone.0213111
Wang Y, Fushimi Y, Arakawa Y, Shimizu Y, Sano K, Sakata A, et al. Evaluation of isocitrate dehydrogenase mutation in 2021 world health organization classification grade 3 and 4 glioma adult-type diffuse gliomas with
doi: 10.1007/s11604-023-01450-x
pubmed: 37819591
Saksø M, Mortensen LS, Primdahl H, Johansen J, Kallehauge J, Hansen CR, et al. Influence of FAZA PET hypoxia and HPV-status for the outcome of head and neck squamous cell carcinoma (HNSCC) treated with radiotherapy: long-term results from the DAHANCA 24 trial (NCT01017224). Radiother Oncol. 2020;151:126–33.
pubmed: 32805273
doi: 10.1016/j.radonc.2020.08.006
Watanabe S, Okamoto S, Hirata K, Shiga T, Toyonaga T, Kobayashi K, et al. First-in-Human Study of [
Liu T, Karlsen M, Karlberg AM, Redalen KR. Hypoxia imaging and theranostic potential of [
pubmed: 32274601
pmcid: 7145880
doi: 10.1186/s13550-020-00621-5
Dias AH, Hansen AK, Munk OL, Gormsen LC. Normal values for
doi: 10.1186/s13550-022-00884-0
Caobelli F, Seibel S, Krieger K, Bregenzer C, Viscione M, Silva Mendes AF, et al. First-time rest-stress dynamic whole-body
pubmed: 37103564
pmcid: 10199881
doi: 10.1007/s00259-023-06242-z
Reed MB, Ponce de León M, Vraka C, Rausch I, Godbersen GM, Popper V, et al. Whole-body metabolic connectivity framework with functional PET. Neuroimage. 2023;271: 120030.
pubmed: 36925087
doi: 10.1016/j.neuroimage.2023.120030
Suzuki M, Fushimi Y, Okada T, Hinoda T, Nakamoto R, Arakawa Y, et al. Quantitative and qualitative evaluation of sequential PET/MRI using a newly developed mobile PET system for brain imaging. Jpn J Radiol. 2021;39:669–80.
pubmed: 33641056
doi: 10.1007/s11604-021-01105-9
Satoh Y, Imai M, Ikegawa C, Onishi H. Image quality evaluation of real low-dose breast PET. Jpn J Radiol. 2022;40:1186–93.
pubmed: 35612727
pmcid: 9616787
doi: 10.1007/s11604-022-01293-y
Nakaura T, Naganawa S. Writing medical papers using large-scale language models: a perspective from the Japanese Journal of Radiology. Jpn J Radiol. 2023;41:457–8.
pubmed: 36897551
doi: 10.1007/s11604-023-01408-z
Doi K, Takegawa H, Yui M, Anetai Y, Koike Y, Nakamura S, et al. Deep learning-based detection of patients with bone metastasis from Japanese radiology reports. Jpn J Radiol. 2023;41:900–8.
pubmed: 36988827
doi: 10.1007/s11604-023-01413-2
Alberts IL, Mercolli L, Pyka T, Prenosil G, Shi K, Rominger A, et al. Large language models (LLM) and ChatGPT: what will the impact on nuclear medicine be? Eur J Nucl Med Mol Imaging. 2023;50:1549–52.
pubmed: 36892666
pmcid: 9995718
doi: 10.1007/s00259-023-06172-w
Beam AL, Drazen JM, Kohane IS, Leong T-Y, Manrai AK, Rubin EJ. Artificial intelligence in medicine. N Engl J Med. 2023;388:1220–1.
pubmed: 36988598
doi: 10.1056/NEJMe2206291
Finlayson SG, Subbaswamy A, Singh K, Bowers J, Kupke A, Zittrain J, et al. The clinician and dataset shift in artificial intelligence. N Engl J Med. 2021;385:283–6.
pubmed: 34260843
pmcid: 8665481
doi: 10.1056/NEJMc2104626
Sjögreen Gleisner K, Chouin N, Gabina PM, Cicone F, Gnesin S, Stokke C, et al. EANM dosimetry committee recommendations for dosimetry of
pubmed: 35284969
pmcid: 9015994
doi: 10.1007/s00259-022-05727-7
Pouget J-P, Konijnenberg M, Eberlein U, Glatting G, Gabina PM, Herrmann K, et al. An EANM position paper on advancing radiobiology for shaping the future of nuclear medicine. Eur J Nucl Med Mol Imaging. 2023;50:242–6.
pubmed: 36066665
doi: 10.1007/s00259-022-05934-2